Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Urticaria Or Hives - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Chronic Urticaria Or Hives - Drug Profiles
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic inducible urticaria
Jul 03, 2022: Celldex Therapeutics presents positive interim data from barzolvolimab phase 1b study in chronic spontaneous urticaria at EAACI 2022
Jun 21, 2022: Celldex announces first patient dosed in phase 2 study of barzolvolimab in patients with chronic spontaneous urticaria
May 29, 2022: United BioPharma receives TFDA approval for phase 2 IND for UB-221 to treat chronic spontaneous urticaria
May 19, 2022: Celldex announces acceptance of abstract for barzolvolimab phase 1b results in chronic spontaneous urticaria for late-breaking presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
Mar 26, 2022: Late-breaking phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Mar 01, 2022: Miravo Healthcare announces the Cadian commercial launch of Blexten for patients 4 years of age and older
Feb 26, 2022: Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Feb 18, 2022: Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program
Feb 01, 2022: Positive Dupixent (dupilumab) data across five diseases with underlying type 2 inflammation to be presented at 2022 AAAAI Annual Meeting
Dec 20, 2021: Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
Dec 01, 2021: Mirae Cell Bio establishes stem cell treatment theory for atopic dermatitis and chronic urticaria
Nov 30, 2021: Allakos announces expansion of lirentelimab development into atopic dermatitis, chronic spontaneous urticaria and asthma
Nov 25, 2021: Taiho Pharmaceutical: Announcement of new release of "Vilanoa OD Tablets 20mg" for allergic diseases
Oct 01, 2021: Novartis’ remibrutinib displays quick disease control in urticaria trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Chronic Urticaria Or Hives, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Chronic Urticaria Or Hives, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chronic Urticaria Or Hives - Pipeline by Allakos Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Alvotech ehf, 2022
Chronic Urticaria Or Hives - Pipeline by Amgen Inc, 2022
Chronic Urticaria Or Hives - Pipeline by BCN Peptides SA, 2022
Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, 2022
Chronic Urticaria Or Hives - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, 2022
Chronic Urticaria Or Hives - Pipeline by CoSci Med-Tech Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Curateq Biologics Pvt Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, 2022
Chronic Urticaria Or Hives - Pipeline by Genentech USA Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Genu Pharma Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by GSK plc, 2022
Chronic Urticaria Or Hives - Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by KeifeRx LLC, 2022
Chronic Urticaria Or Hives - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Leo Pharma AS, 2022
Chronic Urticaria Or Hives - Pipeline by Luye Pharma Group Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mirae Cell Bio Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Novartis AG, 2022
Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by OrchestratePharma GmbH, 2022
Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Principia Biopharma Inc, 2022
Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Siolta Therapeutics Inc, 2022
Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by Third Harmonic Bio Inc, 2022
Chronic Urticaria Or Hives - Pipeline by Tianchen Biopharmaceutical (Suzhou) Co Ltd, 2022
Chronic Urticaria Or Hives - Pipeline by TLL Pharmaceutical LLC, 2022
Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, 2022
Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, 2022
Chronic Urticaria Or Hives - Pipeline by ValenzaBio Inc, 2022
Chronic Urticaria Or Hives - Dormant Projects, 2022
Chronic Urticaria Or Hives - Discontinued Products, 2022